anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Previous observational studies have indicated an inverse correlation between circulating sex hormone binding globulin (SHBG) levels and the incidence of polycystic ovary syndrome (PCOS). Nevertheless, conventional observational studies may be susceptible to bias. Consequently, we conducted a two-sample Mendelian randomization (MR) investigation to delve deeper into the connection between SHBG levels and the risk of PCOS.
METHODS: We employed single-nucleotide polymorphisms (SNPs) linked to serum SHBG levels as instrumental variables (IVs). Genetic associations with PCOS were derived from a meta-analysis of GWAS data. Our primary analytical approach relied on the inverse-variance weighted (IVW) method, complemented by alternative MR techniques, including simple-median, weighted-median, MR-Egger regression, and MR Pleiotropy RESidual Sum and Outlier (MR-PRESSO) testing. Additionally, sensitivity analyses were conducted to assess the robustness of the association.
RESULTS: We utilized 289 SNPs associated with serum SHBG levels, achieving genome-wide significance, as instrumental variables (IVs). Our MR analyses revealed that genetically predicted elevated circulating SHBG concentrations were linked to a reduced risk of PCOS (odds ratio (OR) = 0.56, 95% confidence interval (CI): 0.39-0.78, P = 8.30 × 10-4) using the IVW method. MR-Egger regression did not detect any directional pleiotropic effects (P intercept = 0.626). Sensitivity analyses, employing alternative MR methods and IV sets, consistently reaffirmed our results, underscoring the robustness of our findings.
CONCLUSIONS: Through a genetic epidemiological approach, we have substantiated prior observational literature, indicating a potential causal inverse relationship between serum SHBG concentrations and PCOS risk. Nevertheless, further research is needed to elucidate the underlying mechanism of SHBG in the development of PCOS.
Claravis should be administered with a meal (see PRECAUTIONS, Information for Patients).

The recommended dosage range for Claravis is 0.5 to 1 mg/kg/day given in two divided doses with food for 15 to 20 weeks. In studies comparing 0.1, 0.5, and 1 mg/kg/day,8 it was found that all dosages provided initial clearing of disease, but there was a greater need for retreatment with the lower dosages. During treatment, the dose may be adjusted according to response of the disease and/or the appearance of clinical side effects – some of which may be dose related. Adult patients whose disease is very severe with scarring or is primarily manifested on the trunk may require dose adjustments up to 2 mg/kg/day, as tolerated. Failure to take Claravis with food will significantly decrease absorption. Before upward dose adjustments are made, the patients should be questioned about their compliance with food instructions.

The safety of once daily dosing with Claravis has not been established. Once daily dosing is not recommended.

If the total nodule count has been reduced by more than 70% prior to completing 15 to 20 weeks of treatment, the drug may be discontinued. After a period of 2 months or more off therapy, and if warranted by persistent or recurring severe nodular acne, a second course of therapy may be initiated. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth. Long-term use of Claravis, even in low doses, has not been studied, and is not recommended. It is important that Claravis be given at the recommended doses for no longer than the recommended duration. The effect of long-term use of Claravis on bone loss is unknown (see WARNINGS, Skeletal, Bone Mineral Density, Hyperostosis and Premature Epiphyseal Closure).

Contraceptive measures must be followed for any subsequent course of therapy (see PRECAUTIONS).

INFORMATION FOR PHARMACISTS

Access the iPLEDGE system via the internet (www.ipledgeprogram.com) or telephone (1-866-495-0654) to obtain an authorization and the “do not dispense to patient after” date. Claravis must only be dispensed in no more than a 30-day supply.

REFILLS REQUIRE A NEW PRESCRIPTION AND A NEW AUTHORIZATION FROM THE iPLEDGE SYSTEM.

A Claravis Medication Guide must be given to the patient each time Claravis is dispensed, as required by law. This Claravis Medication Guide is an important part of the risk management program for the patient.
This is a Phase 1 dose escalation clinical trial that constitutes 3 dose cohorts with 3 participants per cohort who will receive intravenous doses of allogeneic bone marrow derived allogeneic mesenchymal stromal cells--0.3 million cells/kg, 1.0 million cells/kg, and 3.0 million cells/kg. We will proceed from the lower dose to the next higher dose if there are no safety concerns for each cohort.
PURPOSE: A novel compound which is useful in treating or preventing hypertension and arteriosclerosis is provided to ensure improved body absorption. CONSTITUTION: An olmesartan derivative is denoted by chemical formula 1. A pharmaceutical composition for preventing or treating hypertension or hemorrhage cardiac failure contains the olmesartan derivative of chemical formula 1 or pharmaceutically acceptable salt thereof. The pharmaceutical composition is solid or liquid formulation. The solid formulation is powder, granule, tablet, capsule, and suppository. The liquid formulation is water, propylene glycol solution, suspension, emulsion.
The control group (C): needling into the same site in the AVF with 1 sharp needle at each dialysis (6-12 dialyses) creating a buttonhole tunnel track, where cannulation with a blunt needle is possible. .
The high prevalence and burden of uterine fibroids in women raises questions about the origin of these benign growths. Here, we propose that fibroids should be understood in the context of human evolution, specifically the advent of bipedal locomotion in the hominin lineage. Over the ≥7 million years since our arboreal ancestors left their trees, skeletal adaptations ensued, affecting the pelvis, limbs, hands, and feet. By 3.2 million years ago, our ancestors were fully bipedal. A key evolutionary advantage of bipedalism was the freedom to use hands to carry and prepare food and create and use tools which, in turn, led to further evolutionary changes such as brain enlargement (encephalization), including a dramatic increase in the size of the neocortex. Pelvic realignment resulted in narrowing and transformation of the birth canal from a simple cylinder to a convoluted structure with misaligned pelvic inlet, mid-pelvis, and pelvic outlet planes. Neonatal head circumference has increased, greatly complicating parturition in early and modern humans, up to and including our own species. To overcome the so-called obstetric dilemma provoked by bipedal locomotion and encephalization, various compensatory adaptations have occurred affecting human neonatal development. These include adaptations limiting neonatal size, namely altricial birth (delivery of infants at an early neurodevelopmental stage, relative to other primates) and mid-gestation skeletal growth deceleration. Another key adaptation was hyperplasia of the myometrium, specifically the neomyometrium (the outer two-thirds of the myometrium, corresponding to 90% of the uterine musculature), allowing the uterus to more forcefully push the baby through the pelvis during a lengthy parturition. We propose that this hyperplasia of smooth muscle tissue set the stage for highly prevalent uterine fibroids. These fibroids are therefore a consequence of the obstetric dilemma and, ultimately, of the evolution of bipedalism in our hominin ancestors.
The present invention pertains to methods for preventing reovirus recognition in the treatment of cellular proliferative disorders, and particularly ras-mediated cellular proliferative disorders, in mammals. The mammal may be selected from dogs, cats, sheep, goats, cattle, horses, pigs, mice, humans and non-human primates. The method comprises suppressing or otherwise inhibiting the immune system of the mammal and, concurrently or subsequently, administering to the proliferating cells an effective amount of one or more reoviruses under conditions which result in substantial lysis of the proliferating cells. In particular, the methods provide for reovirus treatment of immunosuppressed or immuno-deficient mammals to treat the proliferative disorders. Immunosuppression,immunoinhibition or otherwise inducing an immunodeficient state in a mammal renders the reovirus more effective. The methods may include the selective removal of immune constituents that may interfere with the systemic delivery of the virus; preventing reovirus recognition by the host immune system; and removal of the virus from an immune suppressed or immune incompetent host following treatment with reovirus. Alternatively, reovirus may be administered to a mammal with a diminished immune response system under conditions which result in substantial lysis of the proliferating cells. Immune systems may be compromised by one or more of the following: an HIV infection; as a side effect of chemotherapy or radiation therapy; by selective removal of B and/or T cell populations; by removal of antibodies (anti-antireovirus antibodies or all antibodies), and the like.
PURPOSE: A pharmaceutical composition containing spinosin or a spinosin-containing crude drug extract is provided to effectively improve memory and learning ability and to effectively prevent and treat cognitive disorders such as dementia and amnesia. CONSTITUTION: A composition for preventing or treating cognitive disorder contains spinosin. The composition also contains one or more extracts selected from a group consisting of Zizyphus jujuba Mill var. inermis, Zizyphus jujuba Mill var. hoonensis, Zizyphus jujuba Mill var. spinosa, Passiflora edulis flavicarpa, Cayaponia tayuya, Desmodium tortuosum, Wilbrandia ebracteata, Strophioblachia fimbricalyx, Clutia abyssinica, and Saccharopolyspora spinosa. The cognitive disorders are dementia or amnesia. A food composition for preventing or treating cognitive disorders contains spinosin. [Reference numerals] (AA) Delay time(seconds); (BB) In the middle of learning; (CC) In the middle of the present experiment; (DD) Control group 3; (EE) Control group 2; (FF) Medicine injected group 1; (GG) Medicine injected group 2; (HH) Medicine injected group 3; (II) Medicine injected group 4; (JJ) Control group 1
Subjects will wear a continuous glucose monitor prior to test to determine normal glucose levels. The morning of the test an IV will be inserted into the subject and insulin and saline drips will be started. Blood glucose levels will be checked every 10 minutes until the subject becomes hypoglycemic. IVs will be stopped at that time and subject will be given skim milk, orange juice or glucose tablets at that time. Blood will be drawn every 15 minutes until blood sugars stabilize. Blood draws will be analyzed to determine glucose, insulin, epinephrine, norepinephrine, glucagon, cortisol, growth hormone and GLP-1 levels. Procedure will be repeated two more times using other glucose methods (skim milk, orange juice or glucose tablets).
Participants receive placebo IV Q3W plus cisplatin 80 mg/m\^2 Q3W plus 5-FU 800 mg/m\^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m\^2 BID on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.
Polyunsaturated fatty acids are used for the treatment of enuresis and incontinence. Treatment of enuresis and incontinence comprises administration of one or more polyunsaturated fatty acids (PUFAs) and/or their derivatives. ACTIVITY : Uropathic. The efficacy of the PUFAs was tested by administration of either a salmon oil concentrate (500 mg) containing at least 35% omega-3 fatty acids, including 18% (C) and 12% (D), and a nutritional supplement containing 500 mg fatty acid ethyl esters with at least 90% omega-3 fatty acids comprising 80% (C) plus (D) and 10% (A) plus heneicosapentaenoic acid to 8 male volunteers 5-16 years old suffering from enuresis. Daily dosage was 1-2 capsules or 1-3 capsules in the case of the nutritional supplement. Efficacy was seen after 1-14 days. A substantial improvement occurred in two cases. In two other cases the product was withdrawn and later re-administered; enuresis occurred after the withdrawal and stopped after the re-administration. Withdrawal of the treatment after 2 years did not result in recurrence of the enuresis. However, two cases treated with the salmon concentrate showed no improvement. MECHANISM OF ACTION : None given in the source material.
In this study the investigator will assess the effectiveness of a care coordination device (a supportive care device) called, Care4AD for reducing burden and stress of caregivers, enhancing patient adherence to scheduled tasks, and increasing Individuals with dementia activity (IWD). The investigator will conduct a 6-month prospective randomized control trial (RCT) of 100 persons with mild to moderately severe dementia to examine changes in caregiver's burden and stress and IWD's physical activity and adherence to scheduled ADLs. Feedback (e.g., reminders about completed/incomplete tasks) will be activated in the intervention group (IG) and de-activated in the control group (CG). The investigator will also use an ADL log and bi-weekly phone interview with a caregiver as gold standards to validate the detection of adherence to scheduled ADLs of interest. Furthermore, the acceptability, perception of benefit, and ease of use of Care4AD will be further assessed using technology acceptance model (TAM). We hypothesize that at 6 months, those in the IG compared to the CG will have less caregiver burden (Zarit Burden Interview (ZBI) (primary outcome), greater IWD adherence to scheduled ADLs (primary outcome), and higher IWD physical function and activity (primary outcome). Secondary outcomes will include caregiver coping (Brief Cope), self-efficacy (Revised Scale for Caregiving Self-Efficacy), and preparedness (Preparedness for Caregiving Scale), and quality of life of IWD (Quality of Life in Alzheimer's disease scale)
This work aimed to investigate the chemical composition, antioxidant activity, antinociceptive effect, and wound healing activity of the Lonicera caprifolium L. flower essential oil (LCEO). Linalool (16.42%), d-limonene (9.99%), and α-cadinol (10.65%) were the most prevalent components of the LCEO. The LCEO revealed moderate DPPH and ABTS radical-scavenging activity. LCEO exhibited potent antinociceptive activity in acetic acid-induced writhing and hot plate-induced pain model; LCEO reduced 73.88 ± 2.78% of writhing and significantly increased pain withdrawal latency in the mice, respectively. The LCEO also presented a potent wound healing effect, with 98.08 ± 1.37% wound closure on the 12th day of treatment. The results of the study demonstrate antioxidant and wound healing potential with antinociceptive effect. To the best of our knowledge, this is the first report on the bioactivities of L. caprifolium L. essential oil.
Part 3: Eligible patients will receive CDX-1140, based on cohort assigned, in 3 week cycles until progression, or intolerance, or two years of treatment. A fixed dose of pembrolizumab will also be given in 3 week cycles.
The method finds application in the pharmaceutical industry for the preparation of the aminoglucoside antibiotic gentamycin B. Th strain Micromonospora purpurea, registered in NBIMCC under No. 8052 is cultivated under aerobic conditions and continuous agitation on nutritive means containing, in wt.%: soya bean groats 2.0-3.5; maize flour 3.0-5.0; maize starch 1.5-3.0; ammonium sulphate 0.3-0.5, sodium chloride 0.25-0.35; cobalt chloride 0.00015-0.0002; calcium carbonate 0.4-0.7. The fermentation process occurs at 33 1 degrees C to the 80th hour, and at 31..1 degrees C from the 81st hour to the end of the process. In the process of fermentation, the reducing sugars are maintained in concentration of 0.5 to 1.5% towards the total volume by feeding limiting substrate. Cultural liquid is produced of high antibiotic titre of gentamycin B. 2 claims
PURPOSE: To provide a depressor exhibiting exceeding serum lipoprotein (a) level depressing action, having high safety and useful for curing or prevention of ischemic heart disease or arterial sclerosis, etc., by including proanthocyanin as an active component. CONSTITUTION: This depressor contains proanthocyanin as an active component. As an extracting raw material of proanthocyanin, a strained draff secondary produced in a wine-squeezing process in producing of red wine or a strained draff in producing of white wine or grape juice, etc., is preferable. Proanthocyanin may be obtained by dissolving 1wt. of an extracting raw material into 2-1000wt. times of solvent, extracting in a range from room temperature to boiling point of the solvent under normal pressure for 2 hours-2 weeks and purifying resultant extract in a method such as an adsorbent treating or a membrane separation, etc. Dose of the proanthocyanin is preferably 0.5-150mg/ day in a dry weight.
The invention provides a method for selecting an influence index by utilizing an automatic mechanism and an electronic device. The method comprises the following steps. Raw data is obtained, and the raw data comprises a body-related variable and a plurality of indexes to be measured corresponding to the body-related variable. Setting the body-related variable as a target parameter. The body-related variables and the indexes to be tested are input into a plurality of model verifications, and the indexes to be tested are sorted according to the output results of the model verifications to obtain ranking data. And calculating the importance of the indexes to be detected according to the ranking data by using the screening conditions so as to select candidate indexes from the indexes to be detected. Finally, the correlation between the candidate index and the body-related variable is calculated to determine the influence index.
AIMS: The short-term risk of moderate-severe cardiac allograft vasculopathy (CAV) after a low-risk positron emission tomography/computed tomography (PET/CT) is unknown, and therefore, there is no guidance on how frequently to perform screening. The aim of this study was to assess the rate of progression to moderate-severe CAV as part of an annual screening programme.
METHODS AND RESULTS: Patients with no history of CAV 2/3 and a low-risk result on initial screening PET/CT (CAV 0/1) were enrolled in the study. The primary outcome was the progression to CAV 2/3 as part of an annual screening programme (within 6-18 months of initial scan). PET CAV results were graded according to a published and externally validated diagnostic criterion for CAV. Over the study period, 231 patients underwent an initial PET/CT and had a subsequent evaluation for CAV. In this cohort, 4.3% of patients progressed to CAV 2/3 at a median of 374 days (interquartile range 363-433). Initial PET CAV grade was the most significant patient characteristic associated with the progression of CAV, with 17% of patients with PET CAV 1 progressing to CAV 2/3 compared with 1.6% with PET CAV 0 (odds ratio 12.4, 95% confidence interval 3.06-50.3).
CONCLUSION: The rate of progression to moderate-severe CAV at 1 year after the lowest-risk PET/CT is low, but approximately 1/6 patients with PET CAV 1 progress to CAV 2/3. Annual screening with PET/CT for select patients with PET CAV 0 may not be warranted. The optimal screening interval awaits confirmation of our findings in multi-centre registries.
The present invention relates to the technical field of a Chinese medical preparation, particularly to cervical syndrome restoring granules as a Chinese medical preparation and a preparation method thereof. The Chinese medical preparation is prepared from white paeony root, clematis root, kudzuvine root, codonopsis pilosula, astragalus root, red sage root, hemlock parsley, pawpaw, cassia twig, nutgrass galingale rhizome, rehmannia root and liquorice. The preparation method comprises: volatile oil is extracted from the hemlock parsley, the nutgrass galingale rhizome and the cassia twig by distilling; an extract liquid is extracted from the kudzuvine root and the other eight medicines; the extract liquid is concentrated into paste; sucrose and dextrin are added to the paste to be uniformly mixed; the paste is granulated and dried; the volatile oil is sprayed in the dried paste to be uniformly mixed to obtain the Chinese medicine preparation. The Chinese medicine preparation has the characteristics for replenishing the blood, benefiting vital energy, activating blood circulation to dissipate blood stasis, dispersing wind and removing dampness, and has obvious therapeutic effects on pain on the neck and nape, difficult movement, pain on the shoulder, numbness on the upper limbs or muscular dystrophy, etc. caused by cervical spondylosis. The clinical cure rate of the Chinese medical preparation can reach more than 85%.
Motor complete SCI is defined as American Spinal Injury Association (ASIA) impairment Grade A or B, with no motor function preserved below the level of injury. This in-turn results in significant catastrophic dysfunction and disability to the individual's physical and mental health, reducing quality of life and increasing caregiver burden which translates to high socioeconomic costs. The current treatments for chronic SCI involves aggressive rehabilitation to maximize residual neurological function and devices to compensate for neurological loss. However, neurological improvement is dismal, with 94.4% of patients demonstrating no neurological improvement 5-years post-injury. Experimental and electrophysiological observations revealed that spinal networks have the capacity to generate basic locomotor rhythmicity without supraspinal input to the cord. SCS, consisting of a small array of electrodes surgically implanted into the spinal epidural space stimulates afferent sensory pathways in specific patterns to drive voluntary and autonomically controlled motor responses. Activity-based training in conjunction with SCS has been shown to bolster neuroplasticity and recovery caudal to the injury site. The investigators aim to deliver epidural spinal stimulation via an implanted SCS and together with personalized advanced neuro-rehabilitation to study the improvement of neurological function after chronic SCI.